Insights
Insights From Our Experts
Articles
Recognizing Rare Disease Day: Advancing Hope, Access and Innovation
On Rare Disease Day, we recognize the more than 300 million people worldwide living with rare conditions—individuals who often face long diagnostic journeys, limited treatment options, and barriers to consistent care. At EVERSANA, supporting this community is…
Why Our AI Agency Is So Much More Than ChatGPT for Life Sciences Marketing
AI is everywhere. We can generate emails, social posts, videos and research in seconds. But as Faruk Capan explains in his PM360 article, life sciences marketing requires more than a simple AI tool. It requires speed, compliance, security and human expertise working together. …
Demonstrating the Clinical and Economic Value of Efgartigimod for AChR‑Positive gMG in Canada
Generalized myasthenia gravis (gMG) is a rare autoimmune neuromuscular disease that leads to fluctuating muscle weakness and fatigue, often disrupting daily life. Even with standard therapies, many patients continue to experience persistent symptoms or medication‑related side…
Inside the Shifting Role of Pharma 3PLs: Resilient, Regulated & Ready
Third-party logistics in the pharmaceutical industry must always be considered a strategic partnership, not a transactional handoff. Today’s 3PL is no longer about outsourcing a non-core function. It is about orchestrating a regulated, data-rich, end-to-end value chain. Danny Williams, President of Channel Management &…
EVERSANA Recognized by Vault for the Fifth Consecutive Year
EVERSANA has been recognized by Vault for the fifth consecutive year in its 2026 Consulting Rankings, earning placement in both the: Vault Consulting 50 – North America Health Sciences Consulting category Vault’s annual rankings are informed by verified consultant feedback across the…
Rewiring Commercialization for Biotech’s New Reality
Biotech companies are facing rapid shifts in how therapies are developed, funded and brought to market. New modalities, compressed timelines and smaller patient populations are creating pressures that traditional commercialization models weren’t designed to support. In…
How Pharma Marketers Can Prepare for the Next Wave of Healthcare AI
Large language model platforms are accelerating their move into healthcare. In early 2026, OpenAI launched ChatGPT Health and OpenAI for Healthcare, while Anthropic introduced Claude for Healthcare with an emphasis on enterprise safety and workflow integration.…
Bringing a Breakthrough Rare Disease Therapy to Market with Rapid Speed for Patients
Launching a first‑in‑class therapy for patients, particularly in rare disease, requires more than strong clinical data. It demands speed, precision and a commercialization strategy built for complexity. Precigen’s recent FDA approval and launch of Papzimeos, the first treatment for adults with recurrent respiratory…
Insights from Frontiers Health 2025: The Future of Commercialization Models
As the global healthcare landscape rapidly evolves, traditional launch playbooks are no longer enough. Emerging technologies, shifting pricing dynamics, and rising commercial expectations are reshaping how therapies and medical devices reach patients. At Frontiers Health 2025,…
Insights from Frontiers Health 2025: How European Biotechs Can Navigate the U.S. Market
For European life sciences companies, breaking into the U.S. market means navigating one of the most competitive and complex healthcare ecosystems in the world. This topic was explored last November at Frontiers Health 2025 in a…